

ISICEM 2014: Echo Therapeutics to Exhibit at Critical Care Conference



Echo Therapeutics, Inc., a medical device company developing its Symphony® CGM System as a non-invasive, wireless continuous glucose monitoring system, is pleased to announce that its clinical study of Symphony was selected for poster presentation at the 34th International Symposium on Intensive Care and Emergency Medicine (ISICEM) from March 18-21, 2014 in Brussels, Belgium.

The study will be presented by the principal investigator, Jeffrey I. Joseph, D.O., Vice-Chairman and Director of Research, Department of Anesthesiology and Director of the Artificial Pancreas Center at Thomas Jefferson University in Philadelphia, PA, during poster presentations on Tuesday, March 18, 2014 from 6:00-7:00 PM AST. The poster, entitled "Evaluation of Symphony CGM - a Non-Invasive, Transdermal Continuous Glucose Monitoring System for Use in the Critically Ill" (P439), will highlight the positive results from the multi-center clinical trial of Echo's Symphony CGM System in post-surgical patients in hospital intensive care units (ICUs).

"There is great clinical need in the hospital for a continuous glucose monitoring system that is safe, accurate, and easy to use," commented Dr. Joseph. "The prevention of hyperglycemia, hypoglycemia, and glycemic variability in hospitalized patients remains an important clinical goal to decrease morbidity, mortality, length of stay and cost. The Symphony CGM System demonstrated clinically relevant accuracy and excellent safety in a variety of patients and ICU environments. Future studies are needed to determine whether Symphony CGM can be used to direct therapy and improve glucose control in this patient population."

About Echo Therapeutics

Echo Therapeutics is developing the Symphony CGM System as a non-invasive, wireless, continuous glucose monitoring system for use initially in the critical care setting. A significant longer-term opportunity may also exist for Symphony to be used in the hospital beyond the critical care setting, as well as in patients with diabetes in the outpatient setting. Echo has also developed its needle-free skin preparation device, the Prelude® SkinPrep System, as a platform technology to enhance delivery of topical pharmaceuticals.

Source: [Echo Therapeutics](#)

14 March 2014

Published on : Fri, 14 Mar 2014